Related Experiment Video
Updated: Jan 8, 2026
Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model
Published on: August 17, 2022
The survival benefit of deceased donor liver transplantation using MELD 3.0: A contemporary analysis
Gabrielle Jutras1, John P Roberts2, Amy M Shui3
1Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Abstract:
The decision to proceed with liver transplant (LT) must account for the risk of death without LT and the likelihood of survival after, a concept known as "survival benefit." A 2005 study suggested that deceased donor LT (DDLT) survival benefit is achieved at a MELD score of 15, a threshold that persists today. This study reassesses that threshold in the context of MELD 3.0. Data from all adults listed for primary single-organ LT in the UNOS/OPTN registry (January 1, 2021-March 31, 2023) were analyzed. Those undergoing living donor LT were excluded. Using sequential stratification, Cox regression models comparing mortality between LT recipients and waitlist candidates estimated hazard ratios across MELD 3.0 subgroups. Among 21,594 LT candidates (median MELD 3.0, 22, IQR 16-30), LT recipients had a 95% lower adjusted mortality risk than waitlisted candidates (HR 0.05, 95% CI 0.04-0.07, p <0.001). This survival benefit varied by MELD 3.0 score, with an advantage emerging at MELD 3.0 ≥12. At MELD 3.0 of 12-14, DDLT reduced mortality by 46% (HR 0.54, 95% CI 0.30-0.96, p =0.04), while no significant survival benefit was seen below MELD 3.0 of 12, largely due to high post-LT mortality. In this analysis of UNOS/OPTN data, DDLT conferred a survival benefit at MELD 3.0 scores ≥12, revising the historical threshold of 15. However, MELD 3.0 alone does not capture the full complexity of LT candidacy. Factors such as refractory ascites, hepatic encephalopathy, frailty, and poor quality of life should also be considered when considering LT for the individual patient.
Insights
The study reevaluates the survival benefit threshold for deceased donor liver transplants (DDLT) using the MELD 3.0 score. DDLT shows a survival benefit at MELD 3.0 scores of 12 and above, revising the previous threshold of 15.
Area of Science:
- Hepatology
- Transplant Surgery
- Medical Statistics
Background:
- The decision for liver transplant (LT) hinges on balancing pre-LT mortality risk with post-transplant survival, termed "survival benefit."
- A 2005 study established a MELD score of 15 as the threshold for deceased donor liver transplant (DDLT) survival benefit, a benchmark that remains influential.
- This study critically examines this threshold using the updated MELD 3.0 scoring system.
Purpose of the Study:
- To reassess the MELD score threshold for achieving survival benefit in deceased donor liver transplantation (DDLT).
- To evaluate the relationship between MELD 3.0 scores and the survival benefit conferred by DDLT.
- To determine if the current MELD score threshold of 15 requires revision in light of MELD 3.0.
Main Methods:
- Analysis of adult primary single-organ liver transplant (LT) candidates listed in the UNOS/OPTN registry from January 1, 2021, to March 31, 2023.
- Exclusion of living donor LT recipients.
- Utilized sequential stratification and Cox regression models to compare mortality between LT recipients and waitlisted candidates across MELD 3.0 score subgroups.
Main Results:
- LT recipients experienced a significantly lower adjusted mortality risk (95% reduction) compared to waitlisted candidates (HR 0.05).
- A survival benefit for DDLT emerged at MELD 3.0 scores of 12 and above.
- At MELD 3.0 scores of 12-14, DDLT reduced mortality by 46% (HR 0.54); no significant benefit was observed below MELD 3.0 of 12 due to higher post-LT mortality.
Conclusions:
- The MELD 3.0 score indicates that DDLT confers a survival benefit starting at a score of 12, challenging the long-standing threshold of 15.
- While MELD 3.0 is valuable, it does not encompass all critical factors for LT candidacy, such as ascites, hepatic encephalopathy, frailty, and quality of life.
- Comprehensive patient assessment beyond MELD 3.0 is essential for optimal LT decision-making.
More Related Videos
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...